In many cases of estrogen positive (ER+) BC, the E2–estrogen receptor (ER) complex is involved in malignant transformation and progression, and can be therapeutically targeted with selective estrogen receptor modulators (SERMs) such as tamoxifen, which has been used for the last three decades. This evidence concerns the gene ESR1 and breast cancer.